NK Cell-Based Cancer Immunotherapy
Natural killer (NK) cells are innate lymphoid cells that have a significant role in regulating the defenses against cancer development and certain viral infections. They are equipped with an array of activating and inhibitory receptors that stimulate or diminish NK cell activity, respectively. Inhib...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2016 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (222 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546518804498 |
---|---|
ctrlnum |
(CKB)3800000000216307 (oapen)https://directory.doabooks.org/handle/20.500.12854/54692 (EXLCZ)993800000000216307 |
collection |
bib_alma |
record_format |
marc |
spelling |
Susana Larrucea auth NK Cell-Based Cancer Immunotherapy Frontiers Media SA 2016 1 electronic resource (222 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Natural killer (NK) cells are innate lymphoid cells that have a significant role in regulating the defenses against cancer development and certain viral infections. They are equipped with an array of activating and inhibitory receptors that stimulate or diminish NK cell activity, respectively. Inhibitory receptors include, among others, the MHC class I ligands killer cell immunoglobulin-like receptors (KIR) in humans, and members of the Ly49 family of receptors in mice, and CD94/NKG2A. Activating receptors include cytokine and chemokine receptors, and those that interact with ligands expressed on target cells, such as the natural cytotoxicity receptors or NCRs (NKp30, NKp44 and NKp46), NKG2D, CD244 and DNAM-1. In addition, NK cells express Fc?RIIIA or CD16, the receptor that exerts antibody-dependent cell mediated cytotoxicity (ADCC). NK cells also express the death ligands FasL and TRAIL. The killing or sparing of target cells depends on the integration of distinct signals that originate from NK cell receptors. NK cells spare healthy cells that express normal levels of MHC class I molecules and low amounts of stress-induced self-molecules, whereas they kill target cells that down-regulate MHC class I molecules and/or up-regulate stress-induced self-molecules. The latter are common signatures of virus-infected cells and tumors. All the accumulated knowledge on NK cell biology, along with many clinical observations, is driving multiple efforts to improve the arsenal of NK cell-based therapeutic tools in the fight against malignant diseases. Indeed, NK cell-based immunotherapy is becoming a promising approach for the treatment of many cancers. It is well known that NK cells have a significant role in the anti-tumor effect of therapeutic antibodies that use ADCC as a mechanism of action. In addition to this, administration of autologous and allogeneic NK cells after activation and expansion ex vivo is used in the treatment of cancer. Moreover, adoptive transfer of NK cell lines has been tested in humans, and genetically modified NK cells expressing chimeric antigen receptors are being studied in preclinical models for potential use in the clinic. English NK cells Cytokines NK-92 CAR cancer immunotherapy adoptive cell therapy ADCC 2-88919-934-7 Rafael Solana auth Francisco Borrego auth Raquel Tarazona auth |
language |
English |
format |
eBook |
author |
Susana Larrucea |
spellingShingle |
Susana Larrucea NK Cell-Based Cancer Immunotherapy Frontiers Research Topics |
author_facet |
Susana Larrucea Rafael Solana Francisco Borrego Raquel Tarazona |
author_variant |
s l sl |
author2 |
Rafael Solana Francisco Borrego Raquel Tarazona |
author2_variant |
r s rs f b fb r t rt |
author_sort |
Susana Larrucea |
title |
NK Cell-Based Cancer Immunotherapy |
title_full |
NK Cell-Based Cancer Immunotherapy |
title_fullStr |
NK Cell-Based Cancer Immunotherapy |
title_full_unstemmed |
NK Cell-Based Cancer Immunotherapy |
title_auth |
NK Cell-Based Cancer Immunotherapy |
title_new |
NK Cell-Based Cancer Immunotherapy |
title_sort |
nk cell-based cancer immunotherapy |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2016 |
physical |
1 electronic resource (222 p.) |
isbn |
2-88919-934-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT susanalarrucea nkcellbasedcancerimmunotherapy AT rafaelsolana nkcellbasedcancerimmunotherapy AT franciscoborrego nkcellbasedcancerimmunotherapy AT raqueltarazona nkcellbasedcancerimmunotherapy |
status_str |
n |
ids_txt_mv |
(CKB)3800000000216307 (oapen)https://directory.doabooks.org/handle/20.500.12854/54692 (EXLCZ)993800000000216307 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
NK Cell-Based Cancer Immunotherapy |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548867623911424 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03254nam-a2200385z--4500</leader><controlfield tag="001">993546518804498</controlfield><controlfield tag="005">20231214132957.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2016 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3800000000216307</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/54692</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993800000000216307</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Susana Larrucea</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">NK Cell-Based Cancer Immunotherapy</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (222 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Natural killer (NK) cells are innate lymphoid cells that have a significant role in regulating the defenses against cancer development and certain viral infections. They are equipped with an array of activating and inhibitory receptors that stimulate or diminish NK cell activity, respectively. Inhibitory receptors include, among others, the MHC class I ligands killer cell immunoglobulin-like receptors (KIR) in humans, and members of the Ly49 family of receptors in mice, and CD94/NKG2A. Activating receptors include cytokine and chemokine receptors, and those that interact with ligands expressed on target cells, such as the natural cytotoxicity receptors or NCRs (NKp30, NKp44 and NKp46), NKG2D, CD244 and DNAM-1. In addition, NK cells express Fc?RIIIA or CD16, the receptor that exerts antibody-dependent cell mediated cytotoxicity (ADCC). NK cells also express the death ligands FasL and TRAIL. The killing or sparing of target cells depends on the integration of distinct signals that originate from NK cell receptors. NK cells spare healthy cells that express normal levels of MHC class I molecules and low amounts of stress-induced self-molecules, whereas they kill target cells that down-regulate MHC class I molecules and/or up-regulate stress-induced self-molecules. The latter are common signatures of virus-infected cells and tumors. All the accumulated knowledge on NK cell biology, along with many clinical observations, is driving multiple efforts to improve the arsenal of NK cell-based therapeutic tools in the fight against malignant diseases. Indeed, NK cell-based immunotherapy is becoming a promising approach for the treatment of many cancers. It is well known that NK cells have a significant role in the anti-tumor effect of therapeutic antibodies that use ADCC as a mechanism of action. In addition to this, administration of autologous and allogeneic NK cells after activation and expansion ex vivo is used in the treatment of cancer. Moreover, adoptive transfer of NK cell lines has been tested in humans, and genetically modified NK cells expressing chimeric antigen receptors are being studied in preclinical models for potential use in the clinic.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NK cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cytokines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NK-92</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adoptive cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADCC</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-934-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rafael Solana</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Francisco Borrego</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raquel Tarazona</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:38:56 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-09-30 19:47:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338268200004498&Force_direct=true</subfield><subfield code="Z">5338268200004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338268200004498</subfield></datafield></record></collection> |